Postdoctoral Research Fellow in the One Health Bacteriology group where I perform the following roles:
Funded by Shionogi, China, a Phase 3, multicenter, randomized, double-blind,24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19.
Funded by the Wellcome Trust, this project investigated the role of coagulation and diet in the pathogenesis of Buruli ulcer.
These roles were partly performed in the UK and at KCCR in Ghana.
My leading role was as a project manager and in charge of four study sites when in the UK or Ghana.
Funded by NHIR, UK, this randomized controlled trial evaluating the effect of high dose Rifampicin and Dialkylcarbamoyl chloride (DACC)-coated dressings on outcomes in Mycobacterium ulcerans disease
Funded by EDCTP, this randomized controlled trial evaluating a nitric oxide generating dressing (EDX110) to improve the management of Buruli ulcer disease
Contributed to the Burulipath project as a member of the Skin-NTD Research group under MRC/DFID.
The BURULIPATH project was funded by MRC/DFID to investigate the vaccine potential of polyketide synthase domains previously tested in mice for Buruli ulcer disease.
Funded by the Royal Society, investigated the Hepatitis B and HIV co-infection in Kumasi (HEPIK), Ghana